News & Updates
Filter by Specialty:
Mepolizumab benefits held up over time
Beyond 1 year, the humanized monoclonal antibody mepolizumab maintained real-world efficacy and safety in patients with severe eosinophilic asthma in the REALITI-A cohort study, reports an expert at ERS 2021.
Mepolizumab benefits held up over time
25 Sep 2021
Adding cyclophosphamide to glucocorticoids confers no survival benefit in IPF
Adding cyclophosphamide to glucocorticoid treatment in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was associated with a numerically increased risk of mortality, according to results of the phase III EXAFIP trial.
Adding cyclophosphamide to glucocorticoids confers no survival benefit in IPF
24 Sep 2021
SARS-CoV-2 lurks in small airborne particles
Investigations into the role of small aerosol particles in COVID-19 transmission suggest that SARS-CoV-2 may be an airborne hazard. A recent medRxiv preprint study from Singapore adds to this body of evidence.
SARS-CoV-2 lurks in small airborne particles
24 Sep 2021
The air we breathe in the workplace: Is it safe?
What used to be a place that holds a perception of relative safety and minimal health risk to its occupants, the office now appears to be a place that is inching its way towards the other side of the respiratory health spectrum, with office-related occupational asthma on the rise, according to findings from a UK cross-sectional study presented at ERS 2021.